Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors

We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiati...

Full description

Saved in:
Bibliographic Details
Published in:In vivo (Athens) 2021-05, Vol.35 (3), p.1687-1692
Main Authors: Hayashi, Kana, Tokui, Kotaro, Inomata, Minehiko, Azechi, Kenji, Mizushima, Isami, Takata, Naoki, Taka, Chihiro, Okazawa, Seisuke, Kambara, Kenta, Imanishi, Shingo, Miwa, Toshiro, Hayashi, Ryuji, Matsui, Shoko, Nomura, Satoshi, Tobe, Kazuyuki
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nab-paclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.12428